A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

Daniel P. Van Kammen, Joseph Patrick McEvoy, Steven David Targum, David Kardatzke, Terr I.B. Sebree

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Sertindole is a novel antipsychotic agent with high selectivity for the mesolimbic dopaminergic pathway and nanomolar affinities for dopamine D2, serotonin 5-HT2, and norepinephrine NE(α1) receptors. This 40-day randomized, placebo-controlled, dose-ranging multicenter study was designed to assess the effect of sertindole on previously neuroleptic-responsive, hospitalized schizophrenic patients (n = 205). Sertindole doses began at 4 mg/day and were increased to 8, 12, or 20 mg/day, depending on randomization. Efficacy measures included the Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI). Extrapyramidal symptoms (EPS) were assessed by movement rating scales, EPS-related adverse events, and use of anti-EPS medications. A dose-related improvement was observed for PANSS, BPRS, and CGI, with statistically significant mean differences (P < 0.05) between placebo and 20-mg/day sertindole (decreases from baseline of -5.8 versus -16.9 for PANSS, -4.8 versus -10.4 for BPRS, respectively). The differences in CGI final improvement score between placebo and 20-mg/day sertindole were 3.8 versus 2.9, respectively. EPS-related events were comparable in the placebo and sertindole groups. In conclusion, sertindole 20 mg/day was effective, well tolerated, and not associated with significant motor system abnormalities.

Original languageEnglish (US)
Pages (from-to)168-175
Number of pages8
JournalPsychopharmacology
Volume124
Issue number1-2
DOIs
StatePublished - Apr 15 1996
Externally publishedYes

Fingerprint

Schizophrenia
Brief Psychiatric Rating Scale
Placebos
Antipsychotic Agents
Random Allocation
sertindole
Multicenter Studies
Dopamine
Serotonin
Norepinephrine

Keywords

  • Extrapyramidal symptoms
  • Neuroleptics
  • Placebo
  • Schizophrenia
  • Sertindole

ASJC Scopus subject areas

  • Pharmacology

Cite this

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. / Van Kammen, Daniel P.; McEvoy, Joseph Patrick; Targum, Steven David; Kardatzke, David; Sebree, Terr I.B.

In: Psychopharmacology, Vol. 124, No. 1-2, 15.04.1996, p. 168-175.

Research output: Contribution to journalArticle

Van Kammen, Daniel P. ; McEvoy, Joseph Patrick ; Targum, Steven David ; Kardatzke, David ; Sebree, Terr I.B. / A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. In: Psychopharmacology. 1996 ; Vol. 124, No. 1-2. pp. 168-175.
@article{a12eadfb92af4fdb89dcc040dabe0a03,
title = "A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia",
abstract = "Sertindole is a novel antipsychotic agent with high selectivity for the mesolimbic dopaminergic pathway and nanomolar affinities for dopamine D2, serotonin 5-HT2, and norepinephrine NE(α1) receptors. This 40-day randomized, placebo-controlled, dose-ranging multicenter study was designed to assess the effect of sertindole on previously neuroleptic-responsive, hospitalized schizophrenic patients (n = 205). Sertindole doses began at 4 mg/day and were increased to 8, 12, or 20 mg/day, depending on randomization. Efficacy measures included the Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI). Extrapyramidal symptoms (EPS) were assessed by movement rating scales, EPS-related adverse events, and use of anti-EPS medications. A dose-related improvement was observed for PANSS, BPRS, and CGI, with statistically significant mean differences (P < 0.05) between placebo and 20-mg/day sertindole (decreases from baseline of -5.8 versus -16.9 for PANSS, -4.8 versus -10.4 for BPRS, respectively). The differences in CGI final improvement score between placebo and 20-mg/day sertindole were 3.8 versus 2.9, respectively. EPS-related events were comparable in the placebo and sertindole groups. In conclusion, sertindole 20 mg/day was effective, well tolerated, and not associated with significant motor system abnormalities.",
keywords = "Extrapyramidal symptoms, Neuroleptics, Placebo, Schizophrenia, Sertindole",
author = "{Van Kammen}, {Daniel P.} and McEvoy, {Joseph Patrick} and Targum, {Steven David} and David Kardatzke and Sebree, {Terr I.B.}",
year = "1996",
month = "4",
day = "15",
doi = "10.1007/BF02245618",
language = "English (US)",
volume = "124",
pages = "168--175",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1-2",

}

TY - JOUR

T1 - A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

AU - Van Kammen, Daniel P.

AU - McEvoy, Joseph Patrick

AU - Targum, Steven David

AU - Kardatzke, David

AU - Sebree, Terr I.B.

PY - 1996/4/15

Y1 - 1996/4/15

N2 - Sertindole is a novel antipsychotic agent with high selectivity for the mesolimbic dopaminergic pathway and nanomolar affinities for dopamine D2, serotonin 5-HT2, and norepinephrine NE(α1) receptors. This 40-day randomized, placebo-controlled, dose-ranging multicenter study was designed to assess the effect of sertindole on previously neuroleptic-responsive, hospitalized schizophrenic patients (n = 205). Sertindole doses began at 4 mg/day and were increased to 8, 12, or 20 mg/day, depending on randomization. Efficacy measures included the Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI). Extrapyramidal symptoms (EPS) were assessed by movement rating scales, EPS-related adverse events, and use of anti-EPS medications. A dose-related improvement was observed for PANSS, BPRS, and CGI, with statistically significant mean differences (P < 0.05) between placebo and 20-mg/day sertindole (decreases from baseline of -5.8 versus -16.9 for PANSS, -4.8 versus -10.4 for BPRS, respectively). The differences in CGI final improvement score between placebo and 20-mg/day sertindole were 3.8 versus 2.9, respectively. EPS-related events were comparable in the placebo and sertindole groups. In conclusion, sertindole 20 mg/day was effective, well tolerated, and not associated with significant motor system abnormalities.

AB - Sertindole is a novel antipsychotic agent with high selectivity for the mesolimbic dopaminergic pathway and nanomolar affinities for dopamine D2, serotonin 5-HT2, and norepinephrine NE(α1) receptors. This 40-day randomized, placebo-controlled, dose-ranging multicenter study was designed to assess the effect of sertindole on previously neuroleptic-responsive, hospitalized schizophrenic patients (n = 205). Sertindole doses began at 4 mg/day and were increased to 8, 12, or 20 mg/day, depending on randomization. Efficacy measures included the Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI). Extrapyramidal symptoms (EPS) were assessed by movement rating scales, EPS-related adverse events, and use of anti-EPS medications. A dose-related improvement was observed for PANSS, BPRS, and CGI, with statistically significant mean differences (P < 0.05) between placebo and 20-mg/day sertindole (decreases from baseline of -5.8 versus -16.9 for PANSS, -4.8 versus -10.4 for BPRS, respectively). The differences in CGI final improvement score between placebo and 20-mg/day sertindole were 3.8 versus 2.9, respectively. EPS-related events were comparable in the placebo and sertindole groups. In conclusion, sertindole 20 mg/day was effective, well tolerated, and not associated with significant motor system abnormalities.

KW - Extrapyramidal symptoms

KW - Neuroleptics

KW - Placebo

KW - Schizophrenia

KW - Sertindole

UR - http://www.scopus.com/inward/record.url?scp=0029916389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029916389&partnerID=8YFLogxK

U2 - 10.1007/BF02245618

DO - 10.1007/BF02245618

M3 - Article

VL - 124

SP - 168

EP - 175

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1-2

ER -